1. Estimation of the number of women living with metastatic breast cancer in the United States;Mariotto;Cancer Epidemiol Biomarkers Prev,2017
2. Projecting the prevalence and costs of metastatic breast cancer from 2015 through 2030;Gogate;JNCI Cancer Spectr,2021
3. NIH. Breast: SEER 5-year relative survival rates, 2012-2018. Surveillance, epidemiology, and end results (SEER) program; Available at: https://seer.cancer.gov/statistics-network/explorer/application.html?site=55&data_type=4&graph_type=5&compareBy=sex&chk_sex_3=3&series=9&race=1&age_range=1&stage=106&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_display=2#graphArea Accessed: August 23, 2022.
4. MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC);Goetz;Ann Oncol,2022
5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020